Hospasol

Hospasol is a sterile intravenous solution of sodium hydrogen carbonate, supplied as a solution for injection. It contains sodium hydrogen carbonate as the sole active ingredient and is marketed in the European Union. The product is prescribed for correction of metabolic acidosis and related acid‑base disturbances. It is administered by healthcare professionals under prescription. The formulation is isotonic and designed for rapid infusion in acute care settings.

Hospasol is indicated for several clinical situations where an alkaline buffer is required to restore acid‑base balance. It is commonly used in hospital settings for patients with metabolic derangements.

- Correction of metabolic acidosis in patients with renal failure, sepsis, or drug toxicity. - Alkalinisation of urine to facilitate elimination of certain toxins or to prevent crystal formation. - Adjunctive therapy in hyperkalemia to promote intracellular shift of potassium. - Acid‑base management during cardiac surgery and cardiopulmonary bypass. - Supportive treatment in severe diarrheal loss of bicarbonate.

Adverse reactions to Hospasol are generally related to its electrolyte and volume effects.

Common: - Injection site pain or erythema. - Transient increase in serum sodium (hypernatremia). - Mild metabolic alkalosis. - Fluid overload leading to peripheral edema. - Hypotension during rapid infusion. - Nausea or mild gastrointestinal discomfort. - Fever or chills.

Serious: - Severe metabolic alkalosis with pH >7.55. - Pulmonary edema from excessive volume. - Significant hypernatremia causing neurologic symptoms. - Anaphylactic or severe hypersensitivity reactions. - Cardiac arrhythmias secondary to electrolyte shifts.

When prescribing Hospasol, clinicians should evaluate patient-specific factors to minimize risks associated with electrolyte and fluid balance.

- Assess baseline serum electrolytes, especially sodium, potassium, and bicarbonate. - Monitor arterial blood gases and pH during therapy. - Use caution in patients with congestive heart failure or renal impairment due to risk of fluid overload. - Adjust infusion rate in patients prone to hypotension. - Avoid use in severe metabolic alkalosis. - Consider pregnancy status; safety data are limited. - Review concomitant sodium‑containing solutions to prevent excess sodium load.

Hospasol may interact with other agents that affect acid‑base balance, electrolytes, or fluid status.

Avoid: - Other intravenous bicarbonate solutions, which can cause excessive alkalosis. - High‑dose sodium chloride infusions, increasing risk of hypernatremia. - Loop diuretics combined with aggressive bicarbonate may exacerbate electrolyte disturbances. - Acidifying agents such as ammonium chloride, which counteract the bicarbonate effect.

Use with caution: - Potassium‑binding resins (e.g., sodium polystyrene sulfonate) as shifts in potassium may be unpredictable. - ACE inhibitors or ARBs, which can affect renal handling of electrolytes. - Calcium channel blockers, where rapid pH changes may influence drug binding. - Blood products containing citrate, as citrate metabolism may be altered by bicarbonate administration.